Sai Parenteral's Limited
ListedMainboardHealthcare · NSE / BSE
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical company engaged in the research, development, and manufacturing of formulations, operating across two main segments: branded generic formulations and contract development and manufacturing (CDMO) services for both domestic and international markets. Its product portfolio covers multiple therapeutic areas such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, vitamins, minerals and supplements, analgesics, and dermatology, with offerings available in various dosage forms including injectables, tablets, capsules, liquid orals, and ointments. The company serves a wide customer base including government agencies, pharmaceutical companies, hospitals, and distributors across India, and expanded into exports in FY 2023 after acquiring internationally accredited facilities in Hyderabad, enabling supply to markets like Australia, New Zealand, Southeast Asia, the Middle East, and Africa. Sai Parenteral's operates five manufacturing facilities in India, four in Hyderabad and one through its wholly owned subsidiary Revat Laboratories in Ongole, Andhra Pradesh, all equipped with GMP and global certifications, and as of August 31, 2025, the company had 277 full-time employees.
Price Band
₹372 – ₹392
Issue Size
₹1042.83 L Cr
Lot Size
38 shares
GMP
—
Est. Listing
₹392
at current GMP
Subscribed
1.08x
overall
Open
24 Mar 2026
Close
27 Mar 2026
Allotment
30 Mar 2026
Refund
31 Mar 2026
Demat Credit
1 Apr 2026
Listing
2 Apr 2026
Last updated 6 months ago
Overall Subscription
1.08x
Total Demand
QIB Multiplier
1.73x
Institutions & Funds
NII / HNI
2.45x
High Net-Worth
Retail (RII)
0.12x
Individual Bidders
Category-Wise Subscription Breakup
Live bidding breakdown by institutional, non-institutional, and retail investors
| Category | Shares Offered | Shares Applied / Bid | Times Subscribed |
|---|---|---|---|
| QIB | 2,085,659 | 3,610,266 | 1.73x |
| NIB | 1,564,243 | 3,831,502 | 2.45x |
| HNIs(10L +) | 1,042,829 | 3,707,318 | 3.56x |
| HNIs (2-10L) | 521,414 | 124,184 | 0.24x |
| RETAIL | 3,649,901 | 439,204 | 0.12x |
| Total | 8,864,046 | 11,712,474 | 1.08x |
Application-Wise Breakup
Total unique applications received across retail and HNI tranches
| Category | Applications Reserved | Applications Received | Times Subscribed |
|---|---|---|---|
| RETAIL | 96,050 | 7,651 | 0.08x |
| HNIs(10L +) | 1,960 | 160 | 0.08x |
| HNIs (2-10L) | 980 | 127 | 0.13x |
| Total Applications | 98,990 | 7,938 | 0.08x |
Day-Wise Subscription Progress
About Sai Parenteral's Limited Public Issue & Market Profile
Sai Parenteral's Limited is bringing an initial public offering (IPO) in the Healthcare sector with an aggregate issue size of ₹1,04,28,288 Crores. The shares are offered at a price band of ₹372 to ₹392 per equity share on NSE and BSE. Currently, traders and retail applicants are calculating expected listing gains and break-even points based on unofficial grey market quotations.
Bidding & Quota Instructions:
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 38 shares (approx. ₹14,896 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Allotment Reconciliation Schedule:
Allotment reconciliation will be managed by Bigshare Services Private Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2026-04-01, while un-allotted funds or UPI block mandates will be released on 2026-03-31.
Frequently Asked Questions
What is the issue size and price band for Sai Parenteral's Limited IPO?
The Sai Parenteral's Limited IPO aggregate issue size is ₹1,04,28,288 Crores with an equity price band set at ₹372 to ₹392 per equity share. The retail lot size is 38 shares requiring a minimum capital outlay of approx. ₹14,896.
How can I check Sai Parenteral's Limited IPO live subscription demand?
Live subscription figures are compiled real-time from the NSE and BSE bidding engines. You can track QIB, NII/HNI, and Retail category multiples directly on our dedicated live subscription page.
Where will Sai Parenteral's Limited IPO allotment status be published?
The basis of allotment will be published on the official registrar portal (Bigshare Services Private Limited) and the BSE status verification website on or around 2026-03-30.